Rechallenge of malignant gliomas with Temozolomide – can it be effective?

No standard treatment of recurrent malignant glioma is established. Moreover, it is unclear if rechallenge with Temozolomide is effective. We present here feasibility and first treatment results of a dose dense, individually dose adapted 21-day regimen with Temozolomide for recurrent malignant gliomas. 18 consecutive patients with recurrent malignant gliomas (15 glioblastomas [GBM], 2 anaplastic astrocytomas, 1 anaplastic oligodendroglioma) were treated. The basic data are: median time to first relapse 9.1 months; median Karnofsky Performance Status 60% (9×50+60%; 9×70–100%); median age 51 (32–73) years; gender:…